TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02038894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intubated with Sevoflurane (IS)
Description: Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intubated with Propofol (IP)
Description: Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran - no intubation
Description: A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT00386022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL-GLU GnRH antagonist
Description: A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL-GLU GnRH antagonist
Description: A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen patch
Description: transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen patch
Description: transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
Study: NCT03457519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Children's Automated Respiration Monitor (ChARM)
Description: The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Children's Automated Respiration Monitor (ChARM)
Description: The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
Study: NCT03381755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half-dose ticagrelor
Description: To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose ticagrelor
Description: To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
Study: NCT00387673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatosensory Stimulation and Massed Practice Training
Description: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Somatosensory Stimulation and Massed Practice Training
Description: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Somatosensory Stimulation and Massed Practice Training
Description: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
Study: NCT01722942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD implantation
Description: ventricular ICD implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone hydrochloride
Description: amiodarone prescription
Study: NCT02492854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Single-Use Negative Pressure Dressings
Description: Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith\&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Gauze Dressings
Description: Current standard-of-care dressings used to cover surgical wounds post-operatively.
Study: NCT04492579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle-UHT donor human milk supplementation
Description: Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born \>36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.
Study: NCT02635048

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini Percutaneous Nephrolithotomy
Description: patients undergo PNCL with 18Fr nephrostomy tract

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy
Description: patients undergo PNCL with 24Fr nephrostomy tract
Study: NCT01981733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
Study: NCT02578979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holter
Description: Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
Study: NCT03027648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placement of levonorgestrel-releasing intrauterine system
Description: All the patients accepted treatment of levonorgestrel-releasing intrauterine system
Study: NCT04296487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous chondrocytes
Description: autologous chondrocytes implantation (ACI)
Study: NCT02216773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency assisted liver partition with portal vein ligation (RALPP)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal vein embolization (PVE)
Study: NCT00630565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
Study: NCT01085838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
Study: NCT02426788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Description: Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
Study: NCT03356379

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
Study: NCT03996850

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo SPECT/CT

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT

Intervention type: RADIATION
Intervention: Technetium Tc-99m Sestamibi
Description: Given IV
Study: NCT00630565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow transplantation
Description: Day 0 infusion of bone marrow cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell transplantation
Description: Stem cell infusion (\>48 hours after the last dose of cyclophosphamide)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Day 0 infusion of peripheral blood stem cells

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 165 cGy/dose given twice a day on days -7 through -4.
Study: NCT01046253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30 mg Delayed-Release Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: 30 mg Delayed-Release Capsule
Study: NCT03061565

Intervention type: DRUG
Intervention: erythropoietin
Description: Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.

Intervention type: DRUG
Intervention: Placebos
Description: Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
Study: NCT01751555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen:TDF+3TC+EFV
Description: TDF+3TC+EFV for HIV/HBV co-infection
Study: NCT03069092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise
Description: Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
Study: NCT02158884

Intervention type: DEVICE
Group type: OTHER
Intervention: IDEO brace
Description: All participants will receive the IDEO brace.
Study: NCT04540874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03031964

Intervention type: DEVICE
Intervention: revision multihole acetabular cup
Description: post market study of multi hole revision acetabular cup
Study: NCT01134146

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
Study: NCT02428465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purposeful Parenting
Description: Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
Study: NCT03189784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with movement techniques
Description: patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
Study: NCT03076255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT simulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Description: Given thermoplastic mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Description: Given MID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT imaging
Study: NCT02440633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-OPS-2071
Description: Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
Study: NCT03785210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vancomycin
Description: 125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
Study: NCT01189370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week.
Study: NCT04098393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan 3.2 mg/kg/day
Description: Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
Study: NCT01957436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 6 cycles at 75mg/m²/cycle, one cycle every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 6 cycles at 75mg/m²/cycle, one cycle every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 6 cycles at 75mg/m²/cycle, one cycle every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
Study: NCT02595463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
Study: NCT00646815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone (genotropin)
Description: Dosage regulation will follow the local recommendations of GHD treatment
Study: NCT05976269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.
Study: NCT02794792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin L-proline
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Ipragliflozin L-proline
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral